PHAT:NSD-Phathom Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 9.52

Change

-3.58 (-27.33)%

Market Cap

N/A

Volume

0.01B

Analyst Target

USD 38.33
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.61 (+0.94%)

USD 121.60B
REGN Regeneron Pharmaceuticals Inc

-16.67 (-2.03%)

USD 92.70B
ARGX argenx NV ADR

+5.40 (+0.91%)

USD 35.81B
ALNY Alnylam Pharmaceuticals Inc

-4.35 (-1.62%)

USD 34.69B
BGNE BeiGene Ltd

+1.81 (+0.93%)

USD 22.85B
MRNA Moderna Inc

-1.33 (-3.06%)

USD 21.00B
UTHR United Therapeutics Corporatio..

-0.42 (-0.10%)

USD 16.70B
RPRX Royalty Pharma Plc

-0.15 (-0.58%)

USD 16.11B
INCY Incyte Corporation

-0.10 (-0.12%)

USD 14.67B
SMMT Summit Therapeutics PLC

-1.29 (-6.21%)

USD 13.75B

ETFs Containing PHAT

SURI Simplify Propel Opportuni.. 4.99 % 0.00 %

-0.94 (-3.90%)

N/A
BBP Virtus LifeSci Biotech Pr.. 2.29 % 0.79 %

-0.44 (-3.90%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.27% 63% D 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.27% 63% D 50% F
Trailing 12 Months  
Capital Gain 34.08% 67% D+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.08% 67% D+ 72% C
Trailing 5 Years  
Capital Gain -63.66% 50% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.66% 49% F 21% F
Average Annual (5 Year Horizon)  
Capital Gain -12.01% 29% F 19% F
Dividend Return -12.01% 29% F 18% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.38% 66% D+ 40% F
Risk Adjusted Return -25.35% 30% F 22% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector